Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Transplantation

• Publication date

  2002-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00007890-200205270-00020PMID 12042653
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment with the chimeric anti-IL-2Ralpha basiliximab affects both the IL-2 and IL-15 signalling pathways after clinical kidney transplantation.

  2001cited by this paper
• A population pharmacokinetic screen to identify demographic‐clinical covariates of basiliximab in liver transplantation

  2001cited by this paper
• Functional responses of T cells blocked by anti-CD25 antibody therapy during cardiac rejection.

  2000cited by this paper
• Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.

  1999cited by this paper
• Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.

  1999cited by this paper
• Screening for basiliximab exposure–response relationships in renal allotransplantation

  1999cited by this paper
• Reduction of acute allograft rejection by daclizumab

  1999cited by this paper
• Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group.

  1999cited by this paper
• Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups.

  1998cited by this paper
• Disposition and immunodynamics of basiliximab in liver allograft recipients

  1998cited by this paper
• Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.

  1998cited by this paper
• Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.

  1997cited by this paper
• Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients

  1997cited by this paper
• A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation.

  1997cited by this paper
• Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients.

  1996cited by this paper
• Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assay.

  1995cited by this paper
• Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation.

  1995cited by this paper
• The IL-2 receptor complex: its structure, function, and target genes.

  1993cited by this paper
• Interleukin 2

  1993cited by this paper
• A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation.

  1991cited by this paper
• Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys.

  1991cited by this paper
• Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts.

  1990cited by this paper
• Inhibition of alloresponsive naive and memory T cells by CD7 and CD25 antibodies and by cyclosporine.

  1990cited by this paper
• Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders.

  1990cited by this paper
• Anti-IL2 receptor monoclonal antibody (33B3.1) in prophylaxis of early kidney rejection in humans: a randomized trial versus rabbit antithymocyte globulin.

  1989cited by this paper
• Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody.

  1989cited by this paper
• Early experience with anti-Tac in clinical renal transplantation.

  1989cited by this paper
• A humanized antibody that binds to the interleukin 2 receptor.

  1989cited by this paper
• Interleukin-2: inception, impact, and implications.

  1988cited by this paper
• Interleukin 2 receptor-targeted therapy--rationale and applications in organ transplantation.

  1988cited by this paper
• Prevention of rejection of kidney transplants by monoclonal antibody directed against interleukin 2.

  1987cited by this paper
• Interleukin 2.

  1984cited by this paper
• A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.

  1981cited by this paper
• A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells.

  1981cited by this paper

• Acute rejection on immune-mediated chronic rejection after liver transplantation

  2021cites this paper
• Prevalence and risk factors of T-cell mediated rejection in patients after liver transplantation from deceased donors: a retrospective study over 10 years

  2020cites this paper
• Immunosuppression in Pediatric Liver Transplant

  2019cites this paper
• Design, creation and in vitro testing of a reduced immunogenicity humanized anti-CD25 monoclonal antibody that retains functional activity.

  2019cites this paper
• Development of Murine Monoclonal Antibodies, Characterization and Quantification of Diphtheria Toxoid in Vaccine Batches

  2018cites this paper
• Frontiers of monoclonal antibodies: Applications in medical practices

  2018influential citation
• Acute and Chronic Rejection After Liver Transplantation: What A Clinician Needs to Know.

  2017cites this paper
• Monoclonal Antibody Production against Aspergillus Fumigatus in Ascetic Fluid of Balb / C Mice

  2015cites this paper
• Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers: Integrated Analysis of Intravenous and Subcutaneous, Single- and Multiple-Dose Administration

  2014cites this paper
• Antibody induction versus corticosteroid induction for liver transplant recipients.

  2014cites this paper
• Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies

  2013cites this paper
• Antibody Induction Therapy in Renal Transplant Patients Receiving Calcineurin-Inhibitor Immunosuppressive Regimens

  2012cites this paper
• The Anti‐Interleukin 2 Receptor Antibodies

  2012cites this paper
• FoxP3+, and not CD25+, T cells increase post-transplant in islet allotransplant recipients following anti-CD25+ rATG immunotherapy.

  2012cites this paper
• Structural basis of immunosuppression by the therapeutic antibody daclizumab

  2010cites this paper
• Daclizumab induction therapy in liver transplant recipients with renal insufficiency

  2010cites this paper
• Antibody immunosuppressive therapy in solid-organ transplant

  2010cites this paper
• Antibody immunosuppressive therapy in solid organ transplant

  2010cites this paper
• Impact of Basiliximab on regulatory T‐cells early after kidney transplantation: down‐regulation of CD25 by receptor modulation

  2010cites this paper
• Antibody immunosuppressive therapy in solid-organ transplant: Part I.

  2010cites this paper
• Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation

  2010cites this paper
• Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis.

  2010cites this paper
• Interleukin-2 in CD8+ T cells correlates with Banff score during organ rejection in liver transplant recipients

  2009cites this paper
• Novel Approaches to Immunosuppression in Liver Transplantation

  2009cites this paper
• Two doses of humanized anti-CD25 antibody in renal transplantation

  2009cites this paper
• Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies

  2009cites this paper
• Specific antibodies induced by DNA vaccination with extracellular domain of CD25 gene protect against ConA-induced autoimmune hepatitis.

  2009cites this paper
• Monoclonal antibodies in the therapy of multiple sclerosis

  2008cites this paper
• Review: Innovative monoclonal antibody therapies in multiple sclerosis

  2008cites this paper
• Pharmacokinetics and Immunodynamics of Basiliximab in Pediatric Renal Transplant Recipients on Mycophenolate Mofetil Comedication

  2008cites this paper
• Identification and development of new therapeutics for multiple sclerosis.

  2008cites this paper
• Following-up of a four-dose daclizumab induction therapy without calcineurin inhibitors in a liver transplantation recipient with severe renal dysfunction: a case report.

  2008cites this paper
• Chapter 25 Islet Transplantation for the Treatment of Type I Diabetes

  2008cites this paper
• Monoclonal antibodies in clinical diagnosis: A brief review application

  2008cites this paper
• Daclizumab

  2007cites this paper
• A novel three‐dose regimen of daclizumab in liver transplant recipients with hepatitis C: A pharmacokinetic and pharmacodynamic study

  2006influential citation
• Emerging Monoclonal Antibody Therapies for Multiple Sclerosis

  2006cites this paper
• Risk factors and outcomes analyses at 36 months of a prospective, randomized, multicenter, trial of daclizumab induction in simultaneous kidney-pancreas transplant recipients.

  2005cites this paper
• Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation.

  2005cites this paper
• Immunosuppression in pediatric liver and intestinal transplantation: a closer look at the arsenal.

  2005cites this paper
• A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years.

  2005cites this paper
• Induction and Maintenance of Immunosuppression

  2005cites this paper
• Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids.

  2005cites this paper
• Daclizumab: humanized monoclonal antibody to the interleukin-2 receptor

  2005cites this paper
• Ten-year follow-up of recipients of a kidney or heart transplant who received induction therapy with a monoclonal antibody against the interleukin-2 receptor.

  2004cites this paper
• The fractional excretion of soluble interleukin-2 receptor-&agr; is an excellent predictor of the interleukin-2 receptor-&agr; status after treatment with daclizumab

  2004cites this paper
• Early experience with two‐dose daclizumab in the prevention of acute rejection in cardiac transplantation

  2004cites this paper
• Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?

  2004cites this paper
• Daclizumab induction in solid organ transplantation

  2004cites this paper
• Anti-Interleukin-2 Receptor Antibodies in Transplantation

  2004cites this paper
• Single-dose daclizumab induction therapy in patients with liver transplantation.

  2003cites this paper
• Pediatric liver transplantation with daclizumab induction.

  2003cites this paper
• Pediatric liver transplantation with daclizumab induction1

  2003cites this paper
• Long‐term Safety, Tolerability and Efficacy of Daclizumab (Zenapax®) in a Two‐dose Regimen in Liver Transplant Recipients

  2002cites this paper